Sugi Predict

Sugi Predict / Compounds / SCHEMBL268199

SCHEMBL268199

SCHEMBL268199

COC(=O)c1cc(O)ccc1[N+](=O)[O-]

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.59
▸ CA1 P00915 2/20 0.59
▸ CA2 P00918 2/20 0.59
▸ CA7 P43166 2/20 0.59
▸ CA9 Q16790 2/20 0.59
▸ CA14 Q9ULX7 2/20 0.59
▸ SIRT6 Q8N6T7 1/20 0.57
▸ PDK2 Q15119 1/20 0.54
▸ PDK4 Q16654 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.53
▸ BACE1 P56817 5/20 0.49
▸ PDGFRB P09619 1/20 0.47
▸ FGFR1 P11362 1/20 0.47
▸ PDGFRA P16234 1/20 0.47
▸ FLT1 P17948 1/20 0.47
▸ FGFR3 P22607 1/20 0.47
▸ KDR P35968 1/20 0.47
▸ VCAM1 P19320 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18435 0.87 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL268414 0.85 TDP1 (0.62) SIRT6TDP1BACE1ALDH1A1MEN1
Methane SCHEMBL27600491 0.85 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL10784985 0.85 TDP1 (0.62) CA12CA1CA2CA7CA9
SCHEMBL14397012 0.83 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL4753199 0.83 VCAM1 (0.60) SIRT6TDP1PDGFRBFGFR1PDGFRA
SCHEMBL145815 0.83 SIRT6 (0.57) SIRT6TDP1PDGFRBFGFR1PDGFRA
SCHEMBL9747677 0.83 EGFR (0.43) CA12CA1CA2CA7CA9
SCHEMBL5115555 0.83 CA12 (0.62) CA12CA1CA2CA7CA9
SCHEMBL137523 0.82 SIRT6 (0.56) SIRT6TDP1PDGFRBFGFR1PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111825713-B Hapten and complete antigen preparation method for diethoxy phosphorothioate organophosphorus pesticide and application thereof 广西大学 2023-05-09 — — CN claimed
CN-111825713-A Preparation method and application of hapten and complete antigen for diethoxy thiophosphate organophosphorus pesticide 广西大学 2020-10-27 — — CN claimed
US-4851195-A FOR DETERMINING LIQUID PARTIAL PRESSURE; CONTAINING AN ABSORBER, A FLUORESCER AND BICARBONATE PFIZER HOSPITAL PRODUCTS GROUP, INC. (US) 1989-07-25 — — US claimed
EP-0304248-A2 Carbon dioxide sensor Pfizer Hospital Products Group, Inc. (US) 1989-02-22 — — EP claimed
EP-4731216-A1 HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS Augustine Therapeutics (BE) 2026-04-29 — — EP disclosed
US-12486253-B2 Therapeutics for the degradation of mutant BRAF C4 THERAPEUTICS, INC. (US) 2025-12-02 — — US disclosed
WO-2025104079-A1 SALICYLIC ACID AND PICOLINIC ACID DERIVATIVES AS INHIBITORS OF ENERGY COUPLING FACTOR (ECF) TRANSPORTERS FOR THE TREATMENT OF BACTERIAL INFECTIONS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2025-05-22 — — WO disclosed
US-20250115580-A1 THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF C4 THERAPEUTICS, INC. (US) 2025-04-10 — — US disclosed
WO-2025053222-A1 NOVEL ANTHRANILIC ACID-BASED COMPOUNDS, PIN 1 INHIBITOR, THERAPEUTIC AGENT, AND PREVENTIVE AGENT FOR INFECTIOUS DISEASES, ETC. USING SAME 岡部 隆義 2025-03-13 — — WO disclosed
WO-2024261329-A1 HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2024-12-26 — — WO disclosed
US-20240199581-A1 THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF C4 THERAPEUTICS, INC. (US) 2024-06-20 — — US disclosed
CN-117940133-A Therapeutic agents for degradation of mutant BRAF C4医药公司 2024-04-26 — — CN disclosed
WO-1997023216-A1 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1997-07-03 — — WO disclosed
US-4952719-A Process for the preparation of halo aromatic compounds OCCIDENTAL CHEMICAL CORPORATION (US) 1990-08-28 — — US disclosed
EP-0180057-B1 PROCESS FOR THE PREPARATION OF HALO AROMATIC COMPOUNDS OCCIDENTAL CHEMICAL CORPORATION (US) 1989-08-09 — — EP disclosed
US-4590315-A Process for the preparation of halo aromatic compounds OCCIDENTAL CHEMICAL CORPORATION (US) 1986-05-20 — — US disclosed
EP-0180057-A1 Process for the preparation of halo aromatic compounds OCCIDENTAL CHEMICAL CORPORATION (US) 1986-05-07 — — EP disclosed
US-4205173-A 1-Heterocyclic alkyl-1,2,3,4-tetrahydroquinazolinones and analgesic intermediates thereof PENNWALT CORPORATION (US) 1980-05-27 — — US disclosed
US-4060526-A 1-Heterocyclic alkyl-1,2,3,4-tetrahydroquinazolinones and analgesic intermediates thereof PENNWALT CORPORATION (US) 1977-11-29 — — US disclosed
US-4002662-A HERBICIDES MOBIL OIL CORPORATION (US) 1977-01-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199581-A1 THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF BRAF, NRAS, KRAS CA12 4238/4885CA1 4783/4885CA2 4314/4885
US-12486253-B2 Therapeutics for the degradation of mutant BRAF BRAF, NRAS, KRAS CA12 4238/4885CA1 4783/4885CA2 4314/4885
US-20250115580-A1 THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF BRAF, NRAS, KRAS CA12 4238/4885CA1 4783/4885CA2 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.